Phase 3 SPA win and RMAT designation point aglatimagene toward a BLA, but market skepticism and a single-arm-free path hinge on FDA's read of DFS as sufficient

Candel Therapeutics is a clinical-stage company developing aglatimagene, a gene therapy combined with radiotherapy for intermediate-to-high-risk localized prostate cancer that is not yet approved.

Aglatimagene besadenovec, an adenoviral gene therapy delivering HSV-thymidine kinase plus prodrug valacyclovir combined with radiotherapy, became the first agent to meet a DFS primary endpoint in a 745-patient SPA-governed Phase 3 trial in intermediate-to-high-risk localized prostate cancer. The thesis resolves on whether FDA accepts that DFS data, supported by RMAT designation and rolling review eligibility, as sufficient for approval without a mature overall survival readout. The key risk is regulatory: the agency may require longer follow-up or additional endpoints before granting approval, and persistent post-publication stock weakness suggests investors already price in that possibility.